Answers are grounded in this paper and cite their sources.
The WT1 gene is overexpressed in 80–90% of acute myeloid leukemia (AML) cases, and its expression has been associated with several molecular alterations, i.e., FLT3 and NPM1 mutations, representing a complementary marker for prognostic assessment and measurable residual disease (MRD) monitoring. However, its clinical and prognostic significance in AML has not yet been fully clarified. We retrospectively evaluated WT1 expression at diagnosis and its possible value in MRD assessment in AML patients treated with intensive chemotherapy at the Hematology Units of Siena and Ravenna. WT1 transcript levels were quantified in bone marrow samples at diagnosis and post-induction therapy by standardized RT-qPCR. This study involved 120 AML patients; according to ELN 2022, 44 (36.7%) patients were classified as adverse, 50 (41.7%) as intermediate, and 26 (21.7%) as favorable risk. Median WT1 expression was 4559 copies/104 ABL1 at diagnosis and 122 copies/104 ABL1 after induction therapy. A post-induction WT1 reduction of >2 logs was significantly associated with improved overall survival (OS) and event-free survival, as well as prolonged time to relapse. Combining WT1 reduction with FLT3 status further stratified OS, with the poorest outcome observed in patients with <2-log reduction and persistent FLT3 positivity. Changes in WT1 levels, especially a >2-log reduction after induction therapy, could provide complementary MRD information in AML, including for patients lacking leukemia-specific molecular targets.
No takes yet. Share an insight, caveat, or question.
Cuccaro et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: